Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatoblastoma with ET140203 ARTEMIS^® T cells

Eureka Therapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation to ET140203 for the treatment of hepatoblastoma, a rare childhood tumor in the liver that typically occurs in children under the age of 5.